

**WORLD HEALTH ORGANIZATION**  
Regional Office for the Eastern Mediterranean  
**ORGANISATION MONDIALE DE LA SANTE**  
Bureau régional de la Méditerranée orientale



مَنْظَرَةُ الصَّحَّةِ الْعَالَمِيَّةِ  
المكتب الإقليمي شرق المتوسط

**REGIONAL COMMITTEE FOR THE  
EASTERN MEDITERRANEAN**

EM/RC46/11  
July 1999

**Forty-sixth Session**

Original: Arabic

**Agenda item 11(b)**

**NOMINATION OF A MEMBER STATE FROM THE EASTERN  
MEDITERRANEAN REGION TO THE MANAGEMENT ADVISORY  
COMMITTEE OF THE ACTION PROGRAMME ON ESSENTIAL DRUGS**

**CONTENT**

	<b>page</b>
Introduction .....	1
<b>Annex</b>	
Action programme on essential drugs	
Terms of reference of the Management Advisory Committee .....	3
Agenda of the Eleventh Meeting of the Management Advisory Committee Geneva, 16–19 March 1999 .....	5

## INTRODUCTION

The WHO Action Programme on Essential Drugs (DAP)\* was established in 1981 “to collaborate with countries in ensuring the regular supply at the lowest possible cost and the rational use of a selected number of safe and effective drugs and vaccines of acceptable quality”.

Two committees, with different terms of reference, are currently involved in matters related to the management of the programme: the Committee on Drug Policies, and the Management Advisory Committee. The Annex gives the terms of reference of the Management Advisory Committee, indicating its functions, composition and operation and the agenda of the last meeting.

Since 1990, the Regional Committee has selected members to represent the Eastern Mediterranean Region on the Management Advisory Committee. The following table shows the representation from the Eastern Mediterranean Region since 1989.

## MANAGEMENT ADVISORY COMMITTEE OF THE ACTION PROGRAMME ON ESSENTIAL DRUGS

### Representation of EMR

Country	MAC1 1989	MAC2 1990	MAC3 1991	MAC4 1992	MAC5 1993	MAC6 1994	MAC7 1995	MAC8 1996	MAC9 1997	MAC10 1998	MAC11 1999	MAC12 2000	MAC13 2001	MAC14 2002
Yemen	xxx	xxx												
Tunisia			xxx	xxx										
Syrian Arab Republic			xxx	xxx	xxx									
Egypt					xxx	xxx	xxx							
Pakistan						xxx	xxx	xxx						
Lebanon								xxx	xxx	xxx				
United Arab Emirates									xxx	xxx	xxx			
Islamic Republic of Iran											xxx	xxx	xxx	
New												xxx	xxx	xxx

The membership of the United Arab Emirates will end on 31 December 1999.

\* In 1998, DAP became part of a new department called Essential Drugs and other Medicines (EDM) which, together with Vaccines and other Biologicals (VAB) and Blood Safety and Clinical Technology (BCT), forms the Health Technology and Pharmaceuticals (HTP) cluster in WHO headquarters.

The Regional Committee is therefore invited to select one Member State from the Eastern Mediterranean Region that is currently actively involved in drug policy and programme development for a three-year membership on the Management Advisory Committee of the Action Programme on Essential Drugs, starting 1 January 2000 and ending on 31 December 2002.

In 1999, the Management Advisory Committee meeting was held jointly with the Meeting of Interested Partners of the Health Technology and Pharmaceuticals cluster. As this approach may be formalized from 2000 onwards, it would be particularly appropriate if the Member State selected also has expertise in vaccines and other biologicals and blood safety and clinical technology, which are the other subject matters covered by the Health Technology and Pharmaceuticals cluster, as the elected representative will automatically be eligible to attend the Meeting of Interested Partners if this replaces/complements the Management Advisory Committee.

**Annex****ACTION PROGRAMME ON ESSENTIAL DRUGS****TERMS OF REFERENCE OF THE MANAGEMENT ADVISORY COMMITTEE**

The Management Advisory Committee (MAC) represents the interests and responsibilities of WHO's external partners collaborating with WHO in its Action Programme on Essential Drugs. It acts as an advisory body to the Director-General of WHO, making recommendations on matters related to the policy, strategy, finance, management, monitoring and evaluation of the WHO Action Programme on Essential Drugs (DAP).

**Functions**

- Review, analyse and guide the programme of activities and related budget of DAP and make appropriate recommendations to the Director-General.
- Review the arrangements envisaged by the Director-General for financing and managing DAP.
- Review proposed longer-term plans of action and their financial implications.
- Review financial statements of DAP.
- Review periodic reports evaluating the progress of DAP towards the achievement of its objectives and submit its findings and recommendations to the Director-General.
- Recommend ways of improving, as appropriate, coordination between the activities of DAP and of other relevant programmes and organizations.
- Consider any other matters relating to DAP referred to it by the Director-General, the Director of DAP or any member of the Committee.
- In carrying out its functions, MAC shall be informed of all policy decisions and recommendations concerning DAP or WHO's Revised Drug Strategy (RDS) adopted by the World Health Assembly and the Executive Board.

**Composition***Members*

- The government representatives of those countries which contributed funding in support of DAP's budget in the previous two years.
- Two Member States undertaking drug policy and programme development from each of WHO's six regions selected by the respective Regional Committees for three-year terms.
- Major international organizations collaborating in the implementation of WHO's RDS, such as UNDP, UNICEF, UNIDO and the World Bank.

*Observers*

- Other concerned parties invited by the Director-General to attend as observers.

Members selected from the six regions of WHO may be reappointed. The Chairperson of MAC shall, in principle, be a government representative and shall be elected from and by members of MAC for a period of two years, but, while eligible for re-election, may not serve consecutive terms. The Chairperson shall preside over meetings of MAC and undertake whatever additional duties may be assigned by MAC, in agreement with the Director-General of WHO. Observers are encouraged to take part in the deliberations of the MAC.

### **Operation**

The MAC shall meet once a year. The meeting shall concentrate on reviewing DAP's programme in light of the financial support that will have been pledged and the past, present and future coordination of external support for DAP's principal areas of activity (country support, development work, operational research and management). The meeting shall also review and guide the following years' programme and related budget. The MAC may also meet more often upon the proposal of either its Chairperson or the Director-General of WHO, and with the latter's agreement. The MAC shall decide its method of work, which may include the establishment of a number of functional subcommittees. All such subcommittees shall have an advisory role of MAC. Each MAC meeting shall elect a rapporteur from among its members who shall assist in ensuring that the decisions reached by the meeting are adopted and recorded before its closure. The MAC should, whenever possible, adopt its conclusions by consensus. Director, DAP shall be the Secretary of the MAC.

For these purposes, MAC shall be assisted in its endeavours by the provision by WHO of whatever secretariat and other support services may be considered necessary and reasonable.

---

**HEALTH TECHNOLOGY & PHARMACEUTICALS: FIRST MEETING OF INTERESTED PARTNERS**

Geneva, 16-19 March 1999 — Executive Board Room

incorporating

**ELEVENTH MEETING OF THE MANAGEMENT ADVISORY COMMITTEE**

**\*\*\* AGENDA FOR ESSENTIAL DRUGS AND OTHER MEDICINES SESSION \*\*\***

---

**Wednesday 17 March 1999**

09h30-09h50	Opening of the meeting — <i>Dr Jonathan Quick (EDM)</i>	--
09h50-09h55	Election of Chairperson Election of Rapporteur	--
09h55-10h00	Adoption of draft agenda	WHO/HTP/EDM/MAC(11)/99.2
10h00-10h15	Report of the Tenth Meeting of the Management Advisory Committee	DAP/MAC(9)/98.10
10h15-10h30	<i>Coffee/tea break</i>	
10h30-12h30	EDM activities: 1998-1999	WHO/HTP/EDM/MAC(11)/99.4
	Part I — <i>Dr Jonathan Quick (EDM), Dr German Velasquez (EDM), Dr Enrique Fefer (Regional Adviser, AMRO), Dr Ranjit Roy Chaudhury (Coordinator, Indian Essential Drugs Programme)</i>	
	Discussion	
	Part II — <i>Dr Jonathan Quick (EDM), Dr Hans Hogerzeil (EDM), Dr Sabine Kopp-Kubel (EDM), Dr Xiaorui Zhang (EDM)</i>	
	Discussion	
12h30-14h00	<i>Lunch</i>	
14h00-15h45	EDM activities: 1998-1999 Discussion continued	WHO/HTP/EDM/MAC(11)/99.4
	EDM finances: 1998-1999 — <i>Ms Fabienne Adam (HTP/MSU)</i>	WHO/HTP/EDM/MAC(11)/99.5
	Theme paper: <i>Effective regulation of drugs: what can countries do?</i> Introduction: <i>Dr Sabine Kopp-Kubel (EDM), Dr Eshetu Wondemagegnehu (EDM)</i>	WHO/HTP/EDM/MAC(11)/99.6
15h45-16h00	<i>Coffee/tea break</i>	
16h00-17h00	Theme paper: working group session	WHO/HTP/EDM/MAC(11)/99.6

**Thursday 18 March**

09h00-09h30	Plenary report back on theme paper working group session	--
09h30-10h15	EDM outlook and budget: 2000-2001 <i>Dr Jonathan Quick (EDM), Ms Fabienne Adam (HTP/MSU)</i>	
10h15-10h30	Closure of the EDM Session	--
10h30-11h00	<i>Coffee/tea break</i>	